Large Indian Pharmas Join With Foreign Firms To Develop NCEs
This article was originally published in PharmAsia News
Several leading Indian pharmaceutical companies have joined with foreign firms in a three-year effort to develop new chemical entities. Indian companies include Jubilant Organosys, Nicholas Piramal, Orchid Chemicals and Zydus Cadia. The Indian and foreign companies seek to combine their technology, talent and cost benefits to develop new drugs. Foreign firms see Indian firms as only in the early stages of entering the arena of research for drug discovery. (Click here for more
You may also be interested in...
FDA's COVID-19 Naughty List Now Includes Marketers Of Copper Germ Stoppers, ‘24-Hour’ Hand Sanitizer
Warning letters issued by the US FDA on 28 May target two companies using COVID-19 and other disease-prevention claims to market purported germ-killing products, including a rub touted as 24-hour protection and a line of copper rollers and other implements to disinfect hands and personal items.
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.